ClinicalTrials.gg
CompletedNCT03323658Updated Jan 10, 2023Results posted

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

A Phase 1 interventional study of Bexarotene and Questionnaire Administration in Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia and Breast Ductal Carcinoma In Situ, sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Carcinoma, Intraductal, Noninfiltrating by National Cancer Institute (NCI) — 3 open to participants now, 5 under way, 1 of them phase 3. Carcinoma, Intraductal, Noninfiltrating · National Cancer Institute (NCI).

Enrollment
12th of 13
24 · median 65
Started
2018
with 2 others
Phase 1
5 of 13
none open now
Registered
10th of 13
by date

Among the 13 studies in Carcinoma, Intraductal, Noninfiltrating by National Cancer Institute (NCI), this one is the 12th largest by enrollment, is one of 3 that started in 2018, is one of 5 in phase 1, and was the 10th registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

3 of the 13 studies in Carcinoma, Intraductal, Noninfiltrating by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Intraductal, Noninfiltrating by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer. Bexarotene belongs to a class of drugs that are called rexinoids, and it may reduce the incidence of breast tumors.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the recommended phase II dose of topical bexarotene 1% (weight by weight [w/w]) gel for evaluation in healthy women. (Dose Escalation Group) II. Conduct an intervention of topical 1% bexarotene gel to an unaffected breast of healthy women at high risk for breast cancer for 4 weeks at the maximum tolerated dose (MTD) as determined during the dose escalation group phase to assess bexarotene concentration in the breast tissue. (Dose Expansion Group)

SECONDARY OBJECTIVES:

I. To detect bexarotene concentration in the serum at baseline and at 4 weeks of treatment.

II. To detect bexarotene concentration in the breast tissue at 4 weeks of treatment in the dose escalation group.

III. To investigate the effects of topical bexarotene on serum biomarkers, we will determine the change from baseline in i) lipid biomarkers (total cholesterol, triglycerides, low density lipoprotein [LDL], high density lipoprotein [HDL]), ii) thyroid function biomarkers (thyroid stimulating hormone [TSH], T4, T3), iii) calcium.

EXPLORATORY OBJECTIVE:

I. To examine changes in gene expression associated with retinoid action. (Dose Expansion Group)

OUTLINE: This is a dose-escalation study.

Group 1 will apply 10mg bexarotene topically to one breast every other day (QOD) for 4 weeks; Group 2 will apply 10mg bexarotene topically to one breast every other day (QOD) for 1 week and then daily for 3 weeks after confirmation that toxicity is at an acceptable range; Group 3 will apply 10mg bexarotene topically to one breast every other day (QOD) for 1 week, then daily for 1 week, and then 20mg daily for 2 weeks after confirmation that toxicity is at an acceptable range.

After completion of study treatment, patients are followed up at 30 days.

03

Conditions studied

  • Breast Atypical Ductal Hyperplasia
  • Breast Atypical Lobular Hyperplasia
  • Breast Ductal Carcinoma In Situ
  • Breast Lobular Carcinoma In Situ
  • Invasive Breast Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be at high risk as defined by a history of breast cancer (invasive or ductal breast carcinoma in situ [DCIS]) and be at least 5 years out from diagnosis, or lobular carcinoma in situ (LCIS), or proliferative benign breast disease such atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH) or genetic test confirmation of BRCA 1/2 mutation carrier or have a breast cancer risk assessment >= 1.7% in 5 years or a lifetime risk >= 20%
  • No evidence of disease (in situ or invasive cancer that would normally be treated by resection) at trial entry as determined by the investigator; diagnosis of invasive cancer must be at least 5 years prior to initiation on trial
  • (ECOG) performance status =\< 1 ( >= 70%)
  • Leukocytes >= 3,000/microliter
  • >= 1,500/microliter
  • >= 100,000/microliter
  • Total within normal institutional limits
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 1.5 x institutional (ULN)
  • Creatinine =\< 1.5 x institutional ULN
  • >= 10 g/dL
  • Thyroid-stimulating hormone (TSH) within normal institutional limits
  • Triglycerides =\< 300 mg/dl
  • Total cholesterol =\< 300 mg/dl
  • >= 6 months from all previous breast cancer treatment (including endocrine therapy)
  • Participants must have adequate accessible breast tissue as determined by the treating physician, consisting of one breast unaffected by invasive cancer, which has not been radiated; a history of benign core of this breast will be permitted
  • Participants need to have had any breast imaging with a normal/benign (bi-rads 1 or 2) result within 180 days of day 0 and no further routine breast imaging planned during the course of the study (4 weeks); exception: if the mammogram result was a bi-rads 0 and the imaging work-up (ultrasound and/or magnetic resonance imaging [MRI]) result comes back normal/benign (bi-rads 1 or 2) before treatment initiation, then participant is eligible.
  • For women of ; negative pregnancy testing within 72 hours prior to or on study visit #1 (day 0) and willingness to use adequate during the study intervention; OR defined as any one of the following 1) prior hysterectomy, 2) absence of menstrual period for 1 year in the absence of prior chemotherapy or 3) absence of menstrual period for 2 years in women with a prior history of chemotherapy exposure who were pre-menopausal prior to chemotherapy; in women of childbearing potential, effective contraception must be used for one month prior to the initiation of therapy, during therapy, and for at least one month following discontinuation of therapy; it is recommended that two reliable forms of contraception be used simultaneously; if participants are interested in enrolling and have not met the requirement for contraception, they will be seen in the clinic in 1 month for re-evaluation once they have met this requirement and ensure all other eligibility criteria is met prior to dose assignment
  • Willingness to comply with all study interventions and follow-up procedures including the ability to apply the study drug to the breast
  • Ability to understand and the willingness to sign a written document
  • Ability to avoid exposure of the treated breast area to sunlight and artificial ultraviolet light during the use of bexarotene gel

Exclusion criteria

Exclusion Criteria:

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to bexarotene gel, oral or topical retinoids
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, thromboembolic disease, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant, or had given birth, or nursed at any time during the last 12 months
  • Women with a history of any cancer within the last 3 years, except for non-melanoma skin cancer; history of breast cancer must be at least > 5 years from diagnosis
  • Prior bilateral breast surgery (mastectomy, segmental mastectomy, or breast augmentation surgery including breast implants or breast reductions) or combination of breast radiation and surgery involving both breasts
  • Prior history or evidence of breast cancer
  • Prior history of confirmed bilateral invasive breast cancer
  • Current use or \< 6 months since use of selective estrogen receptor modulator (SERMS) or aromatase inhibitors or any other treatment for breast cancer prevention or therapy
  • Skin lesions that disrupt the stratum corneum (e.g., eczema, ulceration) or any breakdown of the skin
  • Current use of a retinol containing agent or any retinoid analogue drug within the last 30 days
  • Dietary vitamin A intake >= 5,000 IU/day (as determined by dietary supplementation)
  • Treatment with any investigational drug or investigational biologic within 30 days of initiating study treatment or during the study
  • History of (HIV) or active
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Prevention (bexarotene)

    Group 1 will apply 10mg bexarotene topically to one breast QOD for 4 weeks; Group 2 will apply 10mg bexarotene topically to one breast QOD for 1 week and then daily for 3 weeks after confirmation that toxicity is at an acceptable range; Group 3 will apply 10mg bexarotene topically to one breast QOD for 1 week, then daily for 1 week, and then 20mg daily for 2 weeks after confirmation that toxicity is at an acceptable range.

    Drug: Bexarotene · Other: Questionnaire Administration

Interventions

  • Given topically

    Also known as: 3-methyl TTNEB, LGD1069, Targretin

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Number of Participants With Incidence of Adverse Events (Dose Limiting Toxicities)

    Dose Limiting Toxicity (DLT) is defined as a grade 2 skin adverse event that persists for at least 6 days or any grade 3 or greater adverse event possibly, probably, or definitely related to the study drug. In addition, a DLT will be a grade 2 skin adverse event that recurs and persists for at least 3 days.

    Time frame: 4 weeks of treatment, Up to 30 days after completion of study drug for AE assessments

Secondary outcomes

  1. Number of Participants With Changes in Markers of Systemic Toxicity

    Serum biomarkers to be tested will be total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein, thyroid-stimulating hormone, T4, T3, and calcium. Will be summarized using mean, standard deviation and median (range) for continuous variables at each time point. Wilcoxon rank-sum test may be used to examine the difference of continuous variables between participants' characteristics groups. Will be plotted as functions of time (baseline, week 1, week 2, and week 4). Linear mixed effect model will be applied to model the biomarker change over time for all participants. Appropriate transformation and regression model will be used to ensure the model fit.

    Time frame: Baseline up to 28 days

  2. Number of Participants With Trace Level of Bexarotene Concentration in Plasma Detected

    Plasma concentrations of bexarotene were evaluated in all participants at baseline and at end of study. Plasma samples: ND = Not detected (below the quantitation limit of 0.5 ng/mL) TDL = Trace levels detected (below the LOQ of 0.5ng/mL; estimated value)

    Time frame: baseline and end of treatment, up to 4 weeks

  3. Number of Participants With Bexarotene Concentration in Tissue

    Breast tissue concentrations were available only in those women who underwent breast biopsies. Tissue samples: Not detected (below the quantitation limit of 2.5 ng/g for a 10mg sample) and Trace levels detected (below the LOQ of 2.5ng/g; estimated value).

    Time frame: end of treatment, up to 4 weeks

Other outcomes

  1. Tissue Markers

    One of the four cores collected from the core biopsies from baseline (in dose expansion cohort only) and post treatment (all dose expansion cohort participants and optional for dose escalation group) will be formalin-fixed and paraffin embedded (FFPE) for histological analysis. One of the four cores collected from the core biopsies from baseline and post treatment will be placed in RNALater and utilized for gene expression of ribonucleic acid (RNA) biomarkers. Gene expression will be performed.

    Time frame: baseline, 15, and Day 28 visits

07

Results

Posted Dec 6, 2022

Participant flow

Women at high risk for breast cancer were recruited for the trial at the Cancer Prevention Center at MD Anderson Cancer Center.

Participant flow — Overall Study
MilestoneDose Level 1Dose Level 2Expansion Cohort
Started10410
Completed10310
Not completed010
Withdrew: Adverse event010

Outcome measures

PrimaryNumber of Participants With Incidence of Adverse Events (Dose Limiting Toxicities)

Dose Limiting Toxicity (DLT) is defined as a grade 2 skin adverse event that persists for at least 6 days or any grade 3 or greater adverse event possibly, probably, or definitely related to the study drug. In addition, a DLT will be a grade 2 skin adverse event that recurs and persists for at least 3 days.

Time frame:
4 weeks of treatment, Up to 30 days after completion of study drug for AE assessments
Reported as:
Count of participants · Participants
Number of Participants With Incidence of Adverse Events (Dose Limiting Toxicities)
ParticipantsDose Level 1Dose Level 2Expansion Cohort
Maculopapular rash with pruritus at application site011
Erythema/redness at application site010
SecondaryNumber of Participants With Changes in Markers of Systemic Toxicity

Serum biomarkers to be tested will be total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein, thyroid-stimulating hormone, T4, T3, and calcium. Will be summarized using mean, standard deviation and median (range) for continuous variables at each time point. Wilcoxon rank-sum test may be used to examine the difference of continuous variables between participants' characteristics groups. Will be plotted as functions of time (baseline, week 1, week 2, and week 4). Linear mixed effect model will be applied to model the biomarker change over time for all participants. Appropriate transformation and regression model will be used to ensure the model fit.

Time frame:
Baseline up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With Changes in Markers of Systemic Toxicity
ParticipantsDose Level 1Dose Level 2Expansion Cohort
Number of Participants With Changes in Markers of Systemic Toxicity001
SecondaryNumber of Participants With Trace Level of Bexarotene Concentration in Plasma Detected

Plasma concentrations of bexarotene were evaluated in all participants at baseline and at end of study. Plasma samples: ND = Not detected (below the quantitation limit of 0.5 ng/mL) TDL = Trace levels detected (below the LOQ of 0.5ng/mL; estimated value)

Time frame:
baseline and end of treatment, up to 4 weeks
Reported as:
Count of participants · Participants
Number of Participants With Trace Level of Bexarotene Concentration in Plasma Detected
ParticipantsDose Level 1Dose Level 2Expansion Cohort
Plasma Baseline Visit000
Plasma End of Treatment Visit002
SecondaryNumber of Participants With Bexarotene Concentration in Tissue

Breast tissue concentrations were available only in those women who underwent breast biopsies. Tissue samples: Not detected (below the quantitation limit of 2.5 ng/g for a 10mg sample) and Trace levels detected (below the LOQ of 2.5ng/g; estimated value).

Time frame:
end of treatment, up to 4 weeks
Reported as:
Count of participants · Participants
Number of Participants With Bexarotene Concentration in Tissue
ParticipantsDose Level 1Dose Level 2Expansion Cohort
Non Detected104
Trace Levels Detected102
Quantitation limit of 2.6-10 ng/g101
Quantitation limit of 11-20 ng/g111
Quantitation limit of 21-30 ng/g100
Quantitation limit of >30 ng/g001
Other pre-specifiedTissue Markers

One of the four cores collected from the core biopsies from baseline (in dose expansion cohort only) and post treatment (all dose expansion cohort participants and optional for dose escalation group) will be formalin-fixed and paraffin embedded (FFPE) for histological analysis. One of the four cores collected from the core biopsies from baseline and post treatment will be placed in RNALater and utilized for gene expression of ribonucleic acid (RNA) biomarkers. Gene expression will be performed.

Time frame:
baseline, 15, and Day 28 visits

Results for this outcome have not been posted.

Adverse events

Collected over 4 weeks of treatment, Up to 30 days after completion of study drug for AE assessments. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 10/10 (0%)0/10 (0%)9/10 (90%)
Dose Level 20/4 (0%)0/4 (0%)4/4 (100%)
Expansion Cohort0/10 (0%)0/10 (0%)10/10 (100%)
Most frequent other events
Showing 10 of 51
Most frequent other events
EventDose Level 1Dose Level 2Expansion Cohort
General Disorders and Administration Site Conditions-Other, SpecifyGeneral disorders8/101/47/10
General Disorders and Administration Site Conditions-Other, SpecifyGeneral disorders3/102/43/10
General Disorders and Administration Site Conditions-Other, SpecifyGeneral disorders3/100/40/10
General Disorders and Administration Site Conditions-Other, SpecifyGeneral disorders0/101/40/10
General Disorders and Administration Site Conditions-Other, SpecifyGeneral disorders1/101/42/10
Tired(Fatigue)General disorders1/101/40/10
General Disorders and Administration Site Conditions-Other, SpecifyGeneral disorders0/101/40/10
General Disorders and Administration Site Conditions-Other, SpecifyGeneral disorders0/101/40/10
General Disorders and Administration Site Conditions-Other, SpecifyGeneral disorders0/101/40/10
Dermatitis (blistering)Immune system disorders0/101/40/10

Baseline characteristics

Age, Customized
Age, Customized(Participants)Dose Level 1Dose Level 2Expansion CohortTotal
40-49 years2013
50-59 years3069
60-69 years53210
70 and over years0112
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1Dose Level 2Expansion CohortTotal
Female1041024
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Level 1Dose Level 2Expansion CohortTotal
Hispanic or Latino0000
Not Hispanic or Latino104923
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Level 1Dose Level 2Expansion CohortTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American2114
White83819
More than one race0000
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(participants)Dose Level 1Dose Level 2Expansion CohortTotal
United States1041024
Menopause
Menopause(Participants)Dose Level 1Dose Level 2Expansion CohortTotal
Pre-Menopausal2035
Post-Menopausal84719
08

Study locations

1 site
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Aug 2021, 37 months.

Results were first posted in Dec 2022, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Oct 27, 2017
StartActual
Jun 15, 2018
Primary completionActual
Aug 3, 2021
CompletionActual
Mar 25, 2022
Results first posted
Dec 6, 2022
Last update
Jan 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03323658
Responsible party
Sponsor
First posted
Oct 27, 2017
Start date
Jun 15, 2018
Primary completion
Aug 3, 2021
Completion
Mar 25, 2022
Results posted
Dec 6, 2022
Last update
Jan 10, 2023

Study contacts

Parijatham (Priya) S Thomas
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bexarotene

Start the discussion